Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma-Reference-Cited by-同舟云学术

Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma

Published:2001-04 Issue:8 Volume:27 Page:821-828
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Shimoni A,Smith TL,Aleman A,Weber D,Dimopoulos M,Anderlini P,Andersson B,Claxton D,Ueno NT,Khouri I,Donato M,Korbling M,Alexanian R,Champlin R,Giralt S

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1703007.pdf

Reference36 articles.

1. Alexanian R, Dimopoulos M . The treatment of multiple myeloma New Engl J Med 1994 330: 484–489

2. Kyle RA . Prognostic factors in multiple myeloma Stem Cells 1995 13: (Suppl. 2) 56–63

3. Attal M, Harousseau J, Stoppa A et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–97

4. Bensinger WI, Rowley SD, Demirer T et al. High dose therapy followed by autologous hematopoietic stem cell infusion for patients with multiple myeloma J Clin Oncol 1996 14: 1447–1456

5. Harousseau J, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma Blood 1995 85: 3077–3085

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study);Frontiers in Oncology;2022-08-30

2. Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial;Bone Marrow Transplantation;2022-04-20

3. Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis;Cancer Cell International;2021-11-10

4. Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved?;Leukemia Research;2021-08

5. Thiotepa intrathecal injections for myelomatous central nervous system involvement;British Journal of Haematology;2021-03-09